New can­cer tar­get? GSK high­lights on­col­o­gy am­bi­tions with its move in­to the clin­ic with RIP1 drug for pan­cre­at­ic can­cer

Re­searchers for Glax­o­SmithK­line are launch­ing a clin­i­cal pro­gram for a RIP1 ki­nase drug in pan­cre­at­ic can­cer af­ter nail­ing down a pos­i­tive look at how this drug worked in mice for pan­cre­at­ic can­cer.

Sci­en­tists at NYU School of Med­i­cine and its Perl­mut­ter Can­cer Cen­ter part­nered with in­ves­ti­ga­tors at GSK on the study, con­clud­ing that the RIP1 ap­proach added to check­point in­hibitors dou­bled the sur­vival time of mice — from 25 days to 50 days.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.